text.skipToContent text.skipToNavigation

{{ addToCartData.mixPtRmWarning }}

您是否要继续?

{{requestQuote.productName}}; {{requestQuote.displayProductCode}}

谢谢

我们将很快回复您的问询。

Something went wrong, please try again later.

快速订购
如不确定,请点击“取消”。您也可保存此商品,稍后再作决定。
取消

{{ favouriteItem.successMessage }}

查看收藏夹

产品已从收藏夹中删除

{{ addToCartData.mixPtRmWarning }}

您是否要继续?

{{requestQuote.productName}}; {{requestQuote.displayProductCode}}

谢谢

我们将很快回复您的问询。

Something went wrong, please try again later.

Product Overview

产品代码

TRC-S885000

CAS登记号

72741-87-8

产品形式

Neat

分子式

C8 H15 N O3

分子量

173.21

Purity

>95% (HPLC)

证明文件

我们应该把您请求的CoA寄到哪里?
产品编号:  {{ coaPopupData.packSize.code }}

{{ errors[0] }}

{{ errors[0] }}

LGC将仅在提供您所需文件时使用您的电子邮件地址。
如需了解有关我们数据处理活动的信息,请访问我们的《隐私声明》
我们应该把您请求的CoA寄到哪里?

请输入您的电子邮件地址,我们将通过电子邮件向您发送批次的相关CoA:
{{ coaPopupData.packSize.coaSelectedLotNumbers }}

{{ errors[0] }}

输入您的电子邮件地址则代表您确认同意LGC不时向您分享与上述产品和其他类似产品有关的信息。 LGC将根据所有适用的数据保护规则和条例处理您的个人数据。有关LGC数据处理的信息,请访问下方的《隐私政策》(见页脚)。
谢谢

我们会将CoA发送到您的电子邮件地址 {{ coaEmailPopupData.userEmail }}

谢谢

您的请求已发送给我们的销售团队处理。

我们应该把您索要的SDS寄到哪里?
产品编号:  {{ sdsPopupData.packSize.code }}

{{ errors[0] }}

{{ errors[0] }}

LGC将仅在提供您所需文件时使用您的电子邮件地址。
如需了解有关我们数据处理活动的信息,请访问我们的《隐私声明》
谢谢

您的请求已发送给我们的销售团队处理。

产品信息

分析物名称

Swainsonine

CAS登记号

72741-87-8

分子式

C8 H15 N O3

分子量

173.21

精确质量测定

173.1052

SMILES

O[C@@H]1CCCN2C[C@@H](O)[C@@H](O)[C@@H]12

InChI

InChI=1S/C8H15NO3/c10-5-2-1-3-9-4-6(11)8(12)7(5)9/h5-8,10-12H,1-4H2/t5-,6-,7-,8-/m1/s1

IUPAC

(1S,2R,8R,8aR)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,2,8-triol

存储温度

-20°C

运输温度

Room Temperature

原产国

CANADA

产品类型

Bioactive Small Molecule

产品形式

Neat

Purity

>95% (HPLC)

Swainsonine is a plant alkaloid derived from Swainsona canescens (a leguminous plant). It is a reversible, active-site directed inhibitor of a-mannosidase at concentrations of 5-10mM. At acid pH, swainsonine resembles an intermediate in the hydrolysis of mannosidases.Swainsonine completely inhibits mammalian Golgi a-mannosidase II (a-3/6-mannosidase in the glycoprotein processing pathway) and mammalian lysosomal a-mannosidase (acid mannosidase). At higher concentrations, swainsonine also inhibits mammalian cytosolic a-mannosidase. It has been shown to inhibit growth of transformed fibroblasts in soft agar and to enhance the antiproliferative effects of INF on murine lymphoreticular tumor cells in vitro. It also blocks the expression of b1-6 branched complex-type oligosaccharides and shunts the pathway towards hybrid-type oligosaccharides. Swainsonine does not appear to inhibit secretion or expression of glycoproteins at the cell surface. Swainsonine is stable for at least 24 h at 37oC in culture media at physiological pH. Working concentration range is 17-1700 ng/ml (0.1-10mM). Swainsonine (at 1 mg/ml) is not cytotoxic and does not inhibit the growth of a variety of mammalian cell lines. Concentrations required to inhibit Golgi a-mannosidase II in vivo may be somewhat higher, as swainsonine tends to concentrate in the acid environment of cell lysosomes, where it exists as a charged cation and does not permeate through membranes readily.Swainsonine blocks the processing of high-mannose oligosaccharides to complex oligosaccharides. Glycoproteins synthesized in the presence of swainsonine tend to carry mostly high-mannose and hybrid oligosaccharide chains. With short treatments (<24 h) with the inhibitor, cells may retain some complex glycoproteins due to asynchronous cell growth and glycoprotein synthesis.

References: J. Biol. Chem., 258, 7578-7585 (1983), Methods Enzymol., 98, 135 (1983), EMBO Journal, 3, 551-556 (1984), Mol. Cell. Biol., 5, 3467-3475 (1985), Int. J. Cancer, 44, 685 (1989),Melanoma Res., 1, 43 (1991), Bonay, P., & Fresno, M.: Glycobiology, 9(5), 423-433 (1999), Klein, J-LD, et al.: Br. J. of Cancer, 80(1/2), 87-95 (1999)

Punchout session timeout warning

Your punchout session will expire in 1 min 59 sec.

Select "Continue session" to extend your session.